JP2022151436A - Agents for treating meningitidis and encephalitis - Google Patents
Agents for treating meningitidis and encephalitis Download PDFInfo
- Publication number
- JP2022151436A JP2022151436A JP2021081960A JP2021081960A JP2022151436A JP 2022151436 A JP2022151436 A JP 2022151436A JP 2021081960 A JP2021081960 A JP 2021081960A JP 2021081960 A JP2021081960 A JP 2021081960A JP 2022151436 A JP2022151436 A JP 2022151436A
- Authority
- JP
- Japan
- Prior art keywords
- encephalitis
- meningitis
- meningitidis
- treating
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、髄膜炎と脳炎の治療薬に関する。The present invention relates to therapeutic agents for meningitis and encephalitis.
髄膜炎と脳炎を根本的に治療する薬がない。There is no drug that cures meningitis and encephalitis fundamentally.
髄膜炎と脳炎を治療薬を提供することを目的とする。The aim is to provide a drug to treat meningitis and encephalitis.
本発明の目的を達成するため、次の構成を採用する。
髄膜炎は脳の周りを覆っている髄膜に、脳炎は脳自体に炎症がおこる病気です
変性剤を人体に投入することにより、髄膜炎と脳炎の原因である身体に侵入した細菌やウイルスなどのＤＮＡとＲＮＡを壊すことにより増殖を防ぎ、髄膜炎と脳炎の治療をする。
細菌やウイルスなど髄膜炎と脳炎の病原体は、核酸を持っている。
核酸とは、ＤＮＡとＲＮＡのことである。
ＤＮＡとＲＮＡは塩基間で水素結合しているが、変性剤を加えてアルカリ性にすると、水素イオンを放出するため変性し、ＤＮＡとＲＮＡの塩基間の水素結合が壊れる。
変性剤を加えてＤＮＡとＲＮＡを壊すことにより、細菌やウイルスの増殖を防ぐことができるため、変性剤という髄膜炎と脳炎の治療薬となる。
髄膜炎と脳炎の部分を標的とする変性剤を有効成分とするリポソーム医薬品として、人体に投与する方法もある。In order to achieve the objects of the present invention, the following configuration is adopted.
Meningitis is a disease in which inflammation occurs in the meninges that surround the brain, and encephalitis is a disease in which inflammation occurs in the brain itself. Prevents proliferation by destroying the DNA and RNA of viruses, etc., and treats meningitis and encephalitis.
Meningitis and encephalitis pathogens, such as bacteria and viruses, carry nucleic acids.
Nucleic acids refer to DNA and RNA.
DNA and RNA are hydrogen-bonded between bases, but when a denaturing agent is added to make them alkaline, hydrogen ions are released and they are denatured, breaking the hydrogen bond between bases of DNA and RNA.
By adding a denaturing agent to destroy DNA and RNA, it is possible to prevent the growth of bacteria and viruses, so the denaturing agent can be used as a remedy for meningitis and encephalitis.
There is also a method of administering to the human body as a liposome drug containing a modifying agent as an active ingredient that targets meningitis and encephalitis.
変性剤という髄膜炎と脳炎の治療薬を人体に投与することにより、髄膜炎と脳炎を治療する。代表的な変性剤は、尿素薬がある。Meningitis and encephalitis are treated by administering meningitis and encephalitis therapeutic agents called degenerative agents to the human body. A representative denaturant is a urea drug.
変性剤という髄膜炎と脳炎の治療薬を手術により、髄膜と脳にそれぞれ注入する。
髄膜炎と脳炎の部分を標的とする変性剤を有効成分とするリポソーム医薬品として、飲み薬として飲むか、注射により投与する。
代表的な変性剤は、尿素薬がある。A treatment for meningitis and encephalitis called a degenerative agent is surgically injected into the meninges and brain, respectively.
As a liposomal drug containing a modifying agent that targets the area of meningitis and encephalitis as an active ingredient, it is taken orally or administered by injection.
A representative denaturant is a urea drug.
特願２０２０－１５５８６２Patent application 2020-155862
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081960A JP2022151436A (en) | 2021-03-26 | 2021-03-26 | Agents for treating meningitidis and encephalitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081960A JP2022151436A (en) | 2021-03-26 | 2021-03-26 | Agents for treating meningitidis and encephalitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022151436A true JP2022151436A (en) | 2022-10-07 |
Family
ID=83464232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021081960A Pending JP2022151436A (en) | 2021-03-26 | 2021-03-26 | Agents for treating meningitidis and encephalitis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2022151436A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003514808A (en) * | 1999-11-16 | 2003-04-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Urea derivatives as anti-inflammatory agents |
| JP2020533329A (en) * | 2017-09-11 | 2020-11-19 | サイティアー セラピューティクス，インコーポレイティド | RAD51 inhibitor |
-
2021
- 2021-03-26 JP JP2021081960A patent/JP2022151436A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003514808A (en) * | 1999-11-16 | 2003-04-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Urea derivatives as anti-inflammatory agents |
| JP2020533329A (en) * | 2017-09-11 | 2020-11-19 | サイティアー セラピューティクス，インコーポレイティド | RAD51 inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Suresh et al. | An update on recent developments in the prevention and treatment of Staphylococcus aureus biofilms | |
| US10463690B2 (en) | Method and compositions for treating cancerous tumors | |
| AR119430A1 (en) | METHODS TO TREAT OR PREVENT SPINAL MUSCULAR ATROPHY | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| JP2022151436A (en) | Agents for treating meningitidis and encephalitis | |
| JP2022151437A (en) | Agents for treating retinitis | |
| JP2022151430A (en) | Agents for treating cholecystitis | |
| JP2022151439A (en) | Agents for treating rhinitis | |
| JP2022151440A (en) | Agents for treating arthritis | |
| JP2022151429A (en) | Agents for treating pancreatitis | |
| JP2022151438A (en) | Agents for treating conchitis and tympanitis | |
| JP2022151428A (en) | Agent for treating nephritis | |
| JP2022151427A (en) | Agents for treating esophagitis | |
| JP2022151433A (en) | Agents for treating cystitis | |
| JP2022151432A (en) | Agents for treating myocarditis and pericarditis | |
| JP2022151431A (en) | Agent for treating enteritis | |
| JP2022146830A (en) | Therapeutic agent for retinal detachment | |
| JP2022151434A (en) | Agents for treating dermatitis | |
| AR120399A1 (en) | A METHOD OF TREATMENT OF A DLL3 POSITIVE CANCER | |
| JP2022146828A (en) | Therapeutic agents for gastritis, gastric ulcer, and duodenal ulcer | |
| JP2022151423A (en) | Agents for treating disc herniation | |
| JP2022124985A (en) | Pneumonia therapeutic drugs | |
| JP2022140193A (en) | Therapeutic agent for rheumatic diseases | |
| JP2022140194A (en) | Therapeutic agent for connective tissue diseases | |
| JP2022151426A (en) | Agents for treating upper respiratory inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210713 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220726 |